Latest Drugwonks' Blog
PCORI is funding mainframe medicine when cloud=based, crowd sourced technologies that integrate genomics, systems biology and patient provided data to match people to treatments. It is investing heavily in PROMIS and it's own CER research network.. both are based on technologies and natural language processing algorithms that are old, clunky and barely accessible to patients.
The new Congress has just launched a 21st century cures initiative. A close look at the legislation and it's goals suggest that PCORI is ill-suited to the goal of using 21st century bioinformatics to increase the role and power patients have over access to new treatments. PCORI is funding yesterday's research methods.
Congress should hold oversight hearing on PCORI and ask some hard questions about it's research focus. It doesn't have to exist at all or in it's current form. Indeed, the money from PCORI and other stand alone pots of money could be integrated into a public-private venture to support biomarker development and precisiono medicine that the legislation calls for.
PCORI had better show it's ready to shift it's gears and mission if it wants to survive.
Here is the committee's press release and the legislation itself. http://1.usa.gov/1BvrGio
A real-world step towards both helping patients now and gathering useful data to advance better care.
PULMONARY FIBROSIS FOUNDATION ANNOUNCES EXPANSION
OF FIRST-OF–ITS-KIND CARE CENTER NETWORK
PFF Adds 12 Sites, Bringing Total to 21 Centers Across the Country
CHICAGO, January 27, 2015 – The Pulmonary Fibrosis Foundation (PFF) today announced the expansion of its PFF Care Center Network with the selection of 12 additional sites, bringing the total number of medical centers to 21 in 20 states. Launched in 2013, the PFF Care Center Network is comprised of leading medical centers with specific expertise in treating pulmonary fibrosis (PF), a group of lung disorders including idiopathic pulmonary fibrosis (IPF) that are often difficult to diagnose and manage and that are associated with survival rates of less than five years following diagnosis in certain diseases.
“As the leading advocate for the pulmonary fibrosis community, we are dedicated to advancing the care of people living with this deadly disease, and this starts with providing greater access to experienced care teams,” said Gregory P. Cosgrove, M.D., chief medical officer of the PFF. “Working together, institutions within the Network will identify and share best practices, which foster better care and ultimately enable more institutions that embrace these practices to be certified as a PFF Care Center site.”
As part of the selection process, a panel of peer reviewers, comprised of current members of the PFF Board of Directors, Medical Advisory Board, PFF Care Center Network and PFF Patient Registry Steering Committee, reviewed and scored applications.
“When selecting sites to add to the PFF Care Center Network, we consider a center’s specific programs and its geographic location in order to best serve the needs of the broader pulmonary fibrosis community,” said Kevin Flaherty, M.D., M.S., chairman of the Steering Committee of the PFF Care Center Network. “The new centers selected provide the highest quality patient care and an individualized approach to treatment in accordance with best evidence-based recommendations. We welcome these new centers and look forward to continuing to expand the Network in the coming year.”
The Pulmonary Fibrosis Foundation Care Center Network
The PFF Care Center Network uses a multidisciplinary approach to deliver comprehensive patient care, forming specialized care teams comprised of experts in interstitial lung disease in pulmonary medicine, rheumatology, radiology and pathology. This multidisciplinary approach is critical to managing a complex disease like PF and ensuring people with PF receive an accurate diagnosis, obtain quality clinical care, and acquire important support services.
The institutions newly certified as PFF Care Center Network sites include:
- Inova Fairfax Medical Campus
- Mayo Clinic in Rochester, Minn.
- Medical University of South Carolina
- New York-Presbyterian/Columbia University Medical Center and New York-Presbyterian/Weill Cornell Medical Center
- Piedmont Healthcare
- The University of Arizona Interstitial Lung Disease Program at the University of Arizona Medical Center-University Campus in Tucson
- The University of Kansas Hospital
- Tulane University School of Medicine
- University of Alabama at Birmingham
- University of Miami Miller School of Medicine
- University of Pennsylvania
Dr. Robert Califf named FDA Deputy Commissioner for Medical Products and Tobacco
U.S. Food and Drug Administration Commissioner Margaret A. Hamburg, M.D., today appointed Robert Califf, M.D., a recognized global leader in cardiology, clinical research, and medical economics, as FDA Deputy Commissioner for Medical Products and Tobacco.
In this position, Dr. Califf will provide executive leadership to the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Healthand the Center for Tobacco Products. He will also oversee the Office of Special Medical Programs in the Office of the Commissioner. Dr. Califf will play a critical role in providing high-level advice and policy direction on the agency’s medical product and tobacco priorities and will manage cross-cutting clinical, scientific and regulatory initiatives in several key areas for the agency, including personalized medicine, orphan drugs, pediatric science, and the advisory committee system.
“I am delighted to announce this important addition to FDA’s senior leadership team,” said FDA Commissioner Margaret A. Hamburg, M.D. “Dr. Califf’s deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalize on, and improve upon, the significant advances we’ve made in medical product development and regulation over the last few years.”
Dr. Califf is currently serving as vice chancellor of clinical and translational research at Duke University. Other prominent roles during his tenure at Duke include director of the Duke Translational Medicine Institute (DTMI), and professor of medicine in the Division of Cardiology at the Duke University Medical Center in Durham, North Carolina. Before serving as director of DTMI, he was the founding director of the Duke Clinical Research Institute, the world’s largest academic research organization. Dr. Califf is recognized by the Institute for Scientific Information as one of the top 10 most cited medical authors, with more than 1,200 peer-reviewed publications.
During his career, Dr. Califf has led many landmark clinical studies, and is a nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health care quality, and clinical research. He is one of our nation’s leaders in the growing field of translational research, which is key to ensuring that advances in science translate into medical care. He was a member of the Institute of Medicine (IOM) committees that recommended Medicare coverage of clinical trials and the removal of ephedra from the market and of the IOM’s Committee on Identifying and Preventing Medication Errors. In addition, he served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board’s Subcommittee on Science and Technology. Currently, he is a member of the IOM Policy Committee and liaison to the Forum in Drug Discovery, Development, and Translation.
Dr. Califf will join the FDA in late February.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human drugs, including vaccines and other biological products for human use, veterinary drugs, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
For a balanced look at the current debate over opioids, check out A Delicate Balance: The challenge of treating pain—and stopping prescription drug abuse—in America. It’s timely, comprehensive, science-based sponsored content in The Atlantic and well worth a read.
ABOUT THIS SERIES
Pain exists. It’s pervasive. And, yet, the drugs prescribed for its treatment are often abused. A Delicate Balance explores several approaches to helping achieve the public health goal of stopping prescription opioid abuse while effectively treating people who live with chronic pain.
To illustrate his point, the President invited Bill Elder, a 27-year-old medical student with a rare form of cystic fibrosis to sit with First Lady Michelle Obama during his speech. Mr. Elder has been using Kalydeco, which, as the president pointed out “has reversed a disease once thought unstoppable” by turning off the genetic mutation causing his disease.
But Kalydeco, is NOT easily available under most health plans. Ask Chloe Jones, a 14-year-old Arkansan with the same type of cystic fibrosis mutation. Arkansas’ Medicaid agency has refused to give her Kalydeco. Instead she has to first fail to respond to older, less-expensive therapies that treat the symptoms but not the underlying cause. (Kalydeco costs about $200,000 a year.) In other words, she has to get sicker and a step closer to death.
Sadly, Chloe is not alone. She and hundreds of thousands of other patients are denied the precision medicines the president celebrates. Instead of ensuring access to precision medicines for the right patient at the right time, pharmacy benefit management companies (PBMs) that put together drug formularies for health plans are only offering drugs from biotech firms that give them biggest cash discount. And then insurers are requiring kids like Chloe to get sicker or pay thousands of dollars before getting targeted treatments.
After the rebates are harvested by PBMs by excluding precision meds, health plans require patients to pay thousands of dollars out of pocket to get the one’s that are left. Managed Care magazine points to a study by Avalere Health that revealed “many insurers require copayments of 10% to 40% for 19 classes of medications for patients with chronic conditions. More than 60% of silver plans put all covered medications for patients with multiple sclerosis, rheumatoid arthritis, Crohn’s disease, and certain cancers in the highest formulary tier.”
While most plans cap out of pocket costs, most consumers can’t afford thousands of dollars upfront. As a result, patients don’t take the medicines that could save their lives. Health insurers and PBMs know it and profit from it.
On top of all that, health plans and PBMs don't pay for the genetic tests that match people to the right medicines. They want randomized clinical trials to demonstrate accuracy know it will take years to set up studies and get results.
The orchestrated outrage over drug prices, led by John Rother and his AHIP funded National Coaltion on Health is nothing but part of cynical plan to extort rebates and limit access to precision medicines. It is noteworthy that AHIP, and the PBMs have contributed nothing to the discussion around the bi-partisan 21st Century Cures Initiative. If they cared about the cost of medicines, they would propose ways to reduce the time and money needed to develop and adopt precision medicine. The same goes for critics who say nothing about the value of medicines and is not an advocate for 21st century cures.
In fact, the pay for play schemes indicate that PBMs and insurers can only profit from precision medicine by rebates. As Eric Topol points out in his new book "The Patient Will See You Now", the health data now controlled by payors and physicians will be generated and controlled by patients themselves. Using smartphones patients will be able to find the right treatment for them based on their genetic and clinical data. Where's the need for middlemen at that point? PBMs are the Blockbuster Video and Tower Record Stores of the healthcare system. NO ONE will miss them when they are gone.
We need to hasten the creative destruction of PBMs. We can start by replacing fail first or step therapy approaches with value-based precision therapy. And we should elimiinate the discriminatory practice to placing precision medicines in the most expensive formlary tiers and the coo-insurance costing thousands. Finally, we need to expand the use of new medicines in the real world.
Ultimately, the rebate and co-pay schemes plump up profits to prop up an outdated business model. PBMs and insurers are skimming off billions of dollars with drug benefit designs that target the most chronically ill and vulnerable patients. No wonder, patient groups have sued health plans for discrimination. Change can't come fast enough.
Are opioids “bad?” Certainly they can be addictive and that fact can’t be understated. That’s precisely why they are controlled substances. And still nascent abuse deterrent technologies are helping to further decrease the opportunities for improper use. But the value of opioids is, when used as directed, they are highly effective in combatting the scourge of pain.
The truth, of course, is that opioids aren’t bad. The problem is that they’re not perfect nor are they perfectly safe – just like 100% of prescription drugs on the market. “Safe” is a relative term. Opioids are safe when they are used as directed. Are chemotherapy drugs “bad” because of their horrible side effects? Of course not. Why – because the alternative is far worse. So too the case with opioids. For both physicians and the tens of millions of Americans with chronic pain, the absence of opioids would be disaster.
That’s why the FDA and other pertinent constituencies view the future of pain medication through the lens of “safe use.” How can we enhance appropriate prescribing, dispensing, and patient behavior? Abuse deterrent technologies are part of the answer, but better physician, pharmacist, and patient education must be another pillar. The FDA has made this a policy priority. FDA Commissioner Hamburg has called for “Improving appropriate prescribing by physicians and use by patients through educational materials required as a part of a risk mitigation strategy for extended-release and long-acting opioids.” Now it's also time for the DEA to work with the FDA to develop smart policies for specific education as a must-have for prescribing rights.Alas, there are too many pundits, politicians, and self-anointed citizen advocates who are keen to focus on placing blame. It’s a savvy strategy for media attention but does little to advance the public health. There’s no value in fixing the blame for medicines that aren’t 100% safe. No medicine is 100% safe. That cynical approach just leverages ignorance to produce anger. There’s tremendous value in fixing the problem – through advancing the safe use of opioids – a crucial weapon in the armamentarium against pain.
Consider the recent spate of litigation against the manufacturers of opioid pain medications. One example is the City of Chicago’s lawsuit against multiple manufacturers of opioid pain treatments. In the United States District Court for the Northern District of Illinois (Eastern Division), the City of Chicago’s First Amended Complaint (“FAC”) seeks to limit the ability of Chicago doctors to treat the chronic, non-cancer pain of patients in the manner doctors deem most appropriate. Although the Food and Drug Administration has approved certain opioid pain medications for the treatment of chronic non-cancer pain, the FAC seeks to deprive patients and doctors of that treatment choice by having six lay jurors determine that “the use of opioids to treat chronic pain is not ‘medically necessary’ or ‘reasonably required’ in that their risks do not exceed their benefits.”
The FDA has determined that opioids serve an important public health role: “When prescribed and used properly, opioids can effectively manage pain and alleviate suffering—clearly a public health priority. Chronic pain is a serious and growing health problem: it affects millions of Americans; contributes greatly to national rates of morbidity, mortality, and disability; and is rising in prevalence. At the same time, there is no dispute that opioids pose significant public health risks: Opioids also have grave risks, the most well-known of which include addiction, overdose, even death. The labeling for these products contains prominent warnings about these risks. Moreover, the boxed warning states that all patients should be routinely monitored for signs of misuse, abuse, and addiction.
In September 2013, the FDA ruled on a citizen’s petition filed by a group of clinicians, researchers, and health officials called Physicians for Responsible Opioid Prescribing (“PROP”). Like the Chicago FAC, the Petition directly challenged the use of opioids for “chronic non-cancer pain.” PROP contended that the “long-term safety and effectiveness of managing [chronic non-cancer pain] with opioids has not been established,” and requested that the FDA, inter alia, impose a “maximum duration of 90-days for continuous (daily) use for non-cancer pain.” The FDA carefully reviewed the Petition and more than 1900 related comments. The agency assessed the relevant literature. It held a two-day public hearing at which it received “over 600 comments” and dozens of experts and concerned citizens testified. The FDA noted that “the majority of comments” “opposed PROP’s requests” and that “many professional societies,” including the American Medical Association, “did not support the Petition and stated that the data cited by PROP did not support PROP’s requests.” After completing a 14-month review, the FDA determined that opioids should continue to be available for the treatment of chronic pain, while also directing further study and certain labeling changes for some opioid drugs. Significantly, after being presented with the same assertions as those now alleged in the Amended Complaint, the FDA made two findings directly at odds with the underlying premises that form the cornerstones of the FAC.
But the lawsuits keep coming. The FDA has the authority, the ability, the means, the mission, and the mandate to manage the health care risks and benefits inherent in the products it regulates on behalf of the American public.
A more balanced legal system will occur only when elected officials determine the time has come for real tort reform, as it affects pharmaceutical companies. But that day is likely very far off. Healthcare leaders must devote their most aggressive efforts toward reform.
Maybe when our elected officials understand that it's the health of their constituents versus the pocketbooks of lawyers, our public servants will finally get serious on tort reform.
Time and again, the dangerous idiots of healthcare reform claim that there's no difference between so-called "me-too" drugs, and that they're simply a way for drug companies to turn a quick profit. The New York Times,in an editorial, claimed that "the nation is wasting billions of dollars on heavily marketed drugs that have never proved themselves in head-to-head competition against cheaper competitors." Wrong.
A recent op-ed in the New York Times, (Why Drugs Cost So Much, NYT, January 14, 2015) by Peter Bach is only the latest in a series of such bandwagon drivel – and he should know better.
The truth is that despite the assertions in and by the New York Times, different drugs are indeed different, even if you describe them as "me-too" medications. Likewise, even though every brand of store-bought peanut butter contains peanuts, oil, sugar, and salt, no one would argue that Skippy and JIF taste exactly the same.
Time and again, different medicines have proved themselves where it counts - in the bodies and biochemistries of patients. No two patients are alike, and the more options available, the more likely doctors are to find what works best for each patient. A few points to consider:
* When patients have access to more effective medications, their overall health improves, even as their overall medical expenses go down. That, in turn, reduces national health-care spending and boosts the economy. Value must be measured in patient outcomes.
* Healthcare innovation saves lives, saves money, promotes economic growth, and provides hope for hundreds of millions of people (both patients and care-givers) in the United States and around the world.
* If we do not support the development of new medicines through timely licensing and fair pricing, innovation will be stopped in its tracks – and that is not an acceptable public health outcome.
* Regulators can be partners in innovation three ways: Through robust oversight, through active collaboration, and, most importantly, by being an innovation enabler.
The deviation between value and pricing in a distinction with a difference – and while both are important, it is value that’s the higher priority since driving patient outcomes is the higher calling (and better long-term economic investment).
After all, as Yale economist William Nordhaus has written, "The social productivity of health care spending might be many times that of other spending.”
Luckily, America's doctors, drug researchers and patients are smarter than that. Just like there aren't any "me-too" patients, there aren't any "me-too" drugs. And if cars and peanut butter are going to be personalized, then medicine is too important not to be.
He writes: "The price of drugs is so unfair and mystifying that publlic often pays a high price when the identical drug is available at a fraction of the cost."
Actually, he didn't write that. It's from another New York Times article: " Drug Prices Here Held Inequitable. " It was written 40 years ago. Burks, E. (1965) Drug Prices Here Held Inequitable. The New York Times Retrieved from https://secure.pqarchiver.com/
What he did write is another variation on this very old theme: "We can free insurers and government programs from the requirement to include all expensive drugs in their plans as we explain to the public that some drugs are not effective enough to justify their price. If we do this, we can be confident that manufacturers will lower their prices to ensure their ability to sell their products. Or we can piggyback on the gumption of bolder countries, and demand that policy makers set drug prices in the United States equal to those of Western Europe. Either approach would be vastly superior to the situation we have today."
First the facts.
1. Nearly 90 percent of all brand drugs are discounted. Companies pay rebates to Medicare, Medicaid, and the Veterans health system. In the private sector (including Obamacare plans) drug firms pay rebates to pharmacy benefit management companies to get preferred listing.
2. Bach is incorrect in claiming insurers have to cover every ‘expensive’ drug. Express Scripts has 66 products on its 2015 formulary exclusion list, compared with 48 in 2014. CVS Caremark’s 2015 list has 95 products, including 72 carryovers from the 2014 edition.
He loves this idea. But what about patients?
From Managed Care Magazine:
"The problem with this approach is that by adding more tiers health plans have confused employees and made some medications more expensive — the antithesis of a value-based strategy. They also have retained cost-sharing mechanisms that make high-priced drugs unaffordable for many patients, Vogenberg says. A 25% copayment on a drug priced at $1,000 a day costs a patient $1,750 each week or more than $7,000 per month. Many patients simply cannot afford their medications, even though commercial plan members often use copayment assistance programs from pharmaceutical manufacturers and can avoid such high cost-sharing amounts, says Brenda Motheral, RPh, MBA, PhD, president of Artemetrx, a specialty drug management consultant.
Bach is silent as PBMs pocket rebates while at the same time sticking patients with the higher costs of meds.
3. Compared to Europe and Canada, on average Americans then pay slightly more for new medicines in exchange for faster and broader access. On average we get twice the new medicines about a year and a half earlier with fewer restrictions. When all is said and done, using Euro-prices would save a grant total of 8.6 billion.. less than one third of one percent of total health care spending."
4. Contrary to Bach, Americans also pay less out of pocket for medicines than in Europe. On average, out of pocket costs are about $800.
4. European speand more on cancer care as a percentage of health care and less on cancer drugs.
Nowhere in Bach's article does he mention the value of broader, faster access to new medicines. Let's stick with the European comparision.
Cancer mortality rates in the US are lower than most anywhere in Europe for every major cancer. And five year survival rates (adjusted for lag time and incidence) are much higher and increase faster. That doesn't include the life years lost when people with advanced forms of cancer die waiting a year and half for a new medicine or have strict limits place on access.
American get broader access to better drugs that save money at about the same price as medicines elsewhere. Price controls and PBM restrictions on access to new drugs actually increases cost and makes people sicker. And probably let a lot of people die waiting for new medcines. If a new medicine adds 3 months on average to the life of a cancer patient it would mean that each year (based on 590,000 cancer deaths a year) someone is denied access robs people with cancer of about 145000 life years annually.
Back claims other systems are vastly superior. The evidence suggests otherwise. Cutting drug prices does kill people.